risk factors for metastatic castration-resistant prostate cancer (crpc) predict long-term treatment with docetaxel转移性前列腺癌castration-resistant(crpc)的危险因素预测长期与多烯紫杉醇治疗.pdfVIP

Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel 1 2 1 1 1 Takashi Kawahara , Yasuhide Miyoshi , Zenkichi Sekiguchi , Futoshi Sano , Narihiko Hayashi , Jun- 2 3 2 1 1 ichi Teranishi , Hiroshi Misaki , Kazumi Noguchi , Yoshinobu Kubota , Hiroji Uemura * 1 Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan, 2 Department of Urology, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan, 3 Department of Urology, Yamato City Hospital, Yamato, Kanagawa, Japan Abstract Purpose: For patients with metastatic castration-resistant prostatic cancer (mCRPC), docetaxel plus prednisone leads to superior survival and a higher response rate compared with mitoxantrone plus prednisone. We analyzed the efficacy of long-term treatment with $10 cycles of docetaxel, and validated the risk group classification in predicting overall survival (OS) in Japanese patients with mCRPC. Patients and Methods: Fifty-two patients with mCRPC were administered 55 mg/m2 docetaxel and 8 mg dexamethasone, every 3 or 4 weeks, simultaneously with hormonal therapy and daily oral dexamethasone. They were divided into two groups, short-term (9 or fewer cycles) and long-term (10 or more cycles). Four risk factors including the presence of anemia, bone metastases, significant pain and visceral metastases were utilized for the risk group classification. Results: Fourteen patients (27%) had an elevation of PSA in spite of docetaxel treatment, while 23 patients (44%) had a de